Topic: mergers and acquisitions
Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.
Gilead Sciences, under pressure from a flagging hep C franchise, agreed to plunk down nearly $12 billion for Kite Pharma just ahead of a blockbuster CAR-T approval.
Samsung inked a novel drug R&D pact with Takeda, GSK China partnered with Alibaba on HPV vaccination, Gland is revising its M&A deal with Fosun.
Zai Lab filed for a $115 million Nasdaq IPO, Takeda formed an R&D deal with Stanford, Fosun and Shanghai Pharma aim to buy a stake in Arbor, and more.
Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.
Gilead Sciences is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.
Samsung launched Remicade biosimilar, Mitsubishi Tanabe bought NeuroDerm for $1.1 billion, Takeda made a drug discovery deal.
Specialists at rare disease drug launches, Cambridge BioMarketing was snapped up by an expansion-minded healthcare services firm, Ireland's UDG.
Australia’s TPI Enterprises has struck a deal to buy the opioid and CMO tablet businesses of Norway’s Vistin Pharma.
Novartis is hunting for bolt-on deals, but too-high biotech valuations have forced its M&A scouts to eye early-stage assets.